Epigenetic Activation of Plasmacytoid DC Drives IFNAR-Dependent Therapeutic Differentiation of AML

In models of AML, leukemia cell differentiation and therapeutic benefit mediated by the histone deacetylases inhibitor panobinostat required activation of the type I interferon pathway.